Risperdal Consta for Bipolar Disorder
type: MedicalStudy
description: A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE3
start date: 2003-11
end date: 2009-12
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00177164
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: University of Pittsburgh
study subject: Bipolar I Disorder
keywords: PHASE3
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Bipolar I Disorder

AI Analytics
type: Organization